AR023390A1 - Terapia para la leucemia mielocitica cronica - Google Patents
Terapia para la leucemia mielocitica cronicaInfo
- Publication number
- AR023390A1 AR023390A1 ARP000101559A ARP000101559A AR023390A1 AR 023390 A1 AR023390 A1 AR 023390A1 AR P000101559 A ARP000101559 A AR P000101559A AR P000101559 A ARP000101559 A AR P000101559A AR 023390 A1 AR023390 A1 AR 023390A1
- Authority
- AR
- Argentina
- Prior art keywords
- myelocitic
- leukemia
- chronic
- therapy
- peg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen los métodos para tratar pacientes que no recibieron tratamiento alguno así como también pacientes que experimentaron algun tratamiento quepadecen de CML, para lograr al menos, una respuesta citogenética parcial; los métodos incluyen administrar una cantidad terapéuticamente efectiva deinterferon-alfa modificado con PEG por ejemplo, interferon alfa-2b modificado con PEG como monoterapia o asociado con una cantidad terapéuticamente efectiva deAra-C.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28836999A | 1999-04-08 | 1999-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR023390A1 true AR023390A1 (es) | 2002-09-04 |
Family
ID=23106810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101559A AR023390A1 (es) | 1999-04-08 | 2000-04-05 | Terapia para la leucemia mielocitica cronica |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP1535624A1 (es) |
| JP (2) | JP2000309541A (es) |
| CN (1) | CN1364089A (es) |
| AR (1) | AR023390A1 (es) |
| AT (1) | ATE297216T1 (es) |
| AU (2) | AU777456B2 (es) |
| BR (1) | BR0009642A (es) |
| CA (1) | CA2303765A1 (es) |
| CO (1) | CO5170411A1 (es) |
| DE (1) | DE60020635T2 (es) |
| DK (1) | DK1043024T3 (es) |
| ES (1) | ES2243166T3 (es) |
| HK (1) | HK1032348A1 (es) |
| HU (1) | HUP0200731A3 (es) |
| MY (1) | MY127276A (es) |
| NO (1) | NO20014850L (es) |
| NZ (1) | NZ514417A (es) |
| PE (1) | PE20010226A1 (es) |
| PT (1) | PT1043024E (es) |
| TW (1) | TWI271196B (es) |
| WO (1) | WO2000061173A2 (es) |
| ZA (1) | ZA200108172B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020977A2 (en) * | 2001-08-31 | 2003-03-13 | The University Court Of The University Of Glasgow | Nucleotide repeats assay |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
-
2000
- 2000-04-05 BR BR0009642-3A patent/BR0009642A/pt not_active IP Right Cessation
- 2000-04-05 MY MYPI20001422A patent/MY127276A/en unknown
- 2000-04-05 TW TW089106223A patent/TWI271196B/zh not_active IP Right Cessation
- 2000-04-05 JP JP2000104045A patent/JP2000309541A/ja not_active Withdrawn
- 2000-04-05 HU HU0200731A patent/HUP0200731A3/hu unknown
- 2000-04-05 CN CN00808569A patent/CN1364089A/zh active Pending
- 2000-04-05 AU AU44515/00A patent/AU777456B2/en not_active Ceased
- 2000-04-05 AR ARP000101559A patent/AR023390A1/es not_active Application Discontinuation
- 2000-04-05 WO PCT/US2000/009038 patent/WO2000061173A2/en active Application Filing
- 2000-04-05 NZ NZ514417A patent/NZ514417A/en not_active IP Right Cessation
- 2000-04-05 CO CO00024855A patent/CO5170411A1/es not_active Application Discontinuation
- 2000-04-06 ES ES00107099T patent/ES2243166T3/es not_active Expired - Lifetime
- 2000-04-06 CA CA002303765A patent/CA2303765A1/en not_active Abandoned
- 2000-04-06 PE PE2000000311A patent/PE20010226A1/es not_active Application Discontinuation
- 2000-04-06 AT AT00107099T patent/ATE297216T1/de active
- 2000-04-06 EP EP05002953A patent/EP1535624A1/en not_active Withdrawn
- 2000-04-06 PT PT00107099T patent/PT1043024E/pt unknown
- 2000-04-06 DK DK00107099T patent/DK1043024T3/da active
- 2000-04-06 DE DE60020635T patent/DE60020635T2/de not_active Expired - Lifetime
- 2000-04-06 EP EP00107099A patent/EP1043024B1/en not_active Expired - Lifetime
-
2001
- 2001-03-26 HK HK01102201A patent/HK1032348A1/xx not_active IP Right Cessation
- 2001-10-04 ZA ZA200108172A patent/ZA200108172B/en unknown
- 2001-10-05 NO NO20014850A patent/NO20014850L/no not_active Application Discontinuation
-
2004
- 2004-12-23 AU AU2004242456A patent/AU2004242456B2/en not_active Ceased
-
2006
- 2006-12-14 JP JP2006337644A patent/JP2007070367A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1043024A3 (en) | 2000-12-20 |
| CN1364089A (zh) | 2002-08-14 |
| NO20014850L (no) | 2001-12-07 |
| ZA200108172B (en) | 2003-01-06 |
| DE60020635D1 (de) | 2005-07-14 |
| DK1043024T3 (da) | 2005-07-04 |
| AU4451500A (en) | 2000-11-14 |
| HUP0200731A2 (en) | 2002-08-28 |
| CO5170411A1 (es) | 2002-06-27 |
| DE60020635T2 (de) | 2006-05-04 |
| JP2000309541A (ja) | 2000-11-07 |
| PE20010226A1 (es) | 2001-02-26 |
| EP1043024A2 (en) | 2000-10-11 |
| TWI271196B (en) | 2007-01-21 |
| AU777456B2 (en) | 2004-10-14 |
| MY127276A (en) | 2006-11-30 |
| CA2303765A1 (en) | 2000-10-08 |
| ES2243166T3 (es) | 2005-12-01 |
| HK1032348A1 (en) | 2001-07-20 |
| WO2000061173A2 (en) | 2000-10-19 |
| AU2004242456A1 (en) | 2005-01-20 |
| PT1043024E (pt) | 2005-10-31 |
| ATE297216T1 (de) | 2005-06-15 |
| EP1535624A1 (en) | 2005-06-01 |
| JP2007070367A (ja) | 2007-03-22 |
| NO20014850D0 (no) | 2001-10-05 |
| WO2000061173A3 (en) | 2001-01-25 |
| NZ514417A (en) | 2003-10-31 |
| HUP0200731A3 (en) | 2002-09-30 |
| EP1043024B1 (en) | 2005-06-08 |
| AU2004242456B2 (en) | 2007-02-15 |
| BR0009642A (pt) | 2002-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4940414A1 (es) | Terapia de interferones polietilenglicol modificados | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| MY126527A (en) | Novel dihydropyrimidines | |
| UY23835A1 (es) | Procedimiento para la preparacion de compuesto de acilo | |
| ES2170141T3 (es) | 4-aminoderivados del acido micofenolico con actividad inmunosupresora. | |
| BR0115162A (pt) | Tratamentos antitumorais eficazes | |
| BR0016831A (pt) | Composição terapêutica e lente de contato impregnada pela mesma | |
| PT1030667E (pt) | Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono | |
| ES2036560T3 (es) | Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. | |
| AR023390A1 (es) | Terapia para la leucemia mielocitica cronica | |
| BR0214564A (pt) | Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos | |
| ECSP003413A (es) | Terapia para la leucemia mielocitica cronica | |
| BR0009644A (pt) | Tratamento de carcinoma de célula renal | |
| DK1287832T3 (da) | Anvendelse af antagonist af leukæmiinhiberende faktor | |
| AR024537A1 (es) | Combinacion sinergica para el tratamiento de enfermedades mediadas virales | |
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| MXPA05007901A (es) | Terapia de combinacion para hcv. | |
| EP1143981A4 (en) | TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS | |
| DE60039122D1 (de) | 6-o-alkyl-2-nor-2-substituierte ketolidderivate | |
| PT1152768E (pt) | Tratamento de infeccoes virais cronicas com m. vaccae | |
| ES2072431T3 (es) | D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores. | |
| GB9903091D0 (en) | Therapeutic nucleoside compound | |
| ECSP003373A (es) | Terapia contra el hiv | |
| AR006382A1 (es) | Procedimiento para el tratamiento del envejecimiento cutaneo y de lesiones atroficas mediante la administracion de una preparacion conteniendoacido hialuronico y/o hialuronatos. | |
| AR023398A1 (es) | Terapia para melanomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |